Others

China’s Drug Quality Control System Shows 99.5% Compliance Rate in 2025 NMPA Report

NeuroGen Pharma Secures Exclusive China Rights to Teva's Ajovy – World's First Dual-Indication CGRP Antagonist for Migraine Prevention
CompanyDeals

NeuroGen Pharma Secures Exclusive China Rights to Teva’s Ajovy – World’s First Dual-Indication CGRP Antagonist for Migraine Prevention

CompanyDeals

Eli Lilly to Acquire Kelonia Therapeutics for $7 Billion to Secure In Vivo CAR-T Platform Targeting Multiple Myeloma

CompanyDrug

CSPC’s Albumin-Bound Sirolimus (HB1901) Meets Primary Endpoint in Phase Ib/III Trial for Rare PEComa, Reinforcing Breakthrough Therapy Status

AI Healthtech Firm WeiMai Files for Hong Kong IPO, Touting CareAI Platform and Leadership in Hospital-Linked Disease Management
CompanyDeals

AI Healthtech Firm WeiMai Files for Hong Kong IPO, Touting CareAI Platform and Leadership in Hospital-Linked Disease Management

CompanyLegal / IP

UPC Appeal Court Reverses Lower Ruling, Imposes Preliminary Injunction on Sinocare’s iCanCGM App in 17 European Countries Following Abbott Patent Claim

CompanyDrug

Hengrui Launches Pediatric Trial of Dual GIPR/GLP-1R Agonist HRS9531 in Overweight and Obese Adolescents Following NMPA Clearance

CompanyDrug

Hengrui’s Trastuzumab Rezetecan Receives CDE Breakthrough Therapy Designation for First-Line HER2+ Metastatic Breast Cancer in Combination with Pertuzumab

CompanyDeals

Biogen Completes Global Consolidation of Felzartamab with $100M Upfront Deal for Greater China Rights from TJ Biopharma

CompanyDrug

Shanghai Leadingtac Secures FDA Clearance for Phase I Trial of LT-010391, First Oral KRAS-G12D Degrader in Clinical Development

Policy / Regulatory

China Tightens Control Over Pregabalin and Dextromethorphan-Guaifenesin Preparations Amid Abuse Concerns; NMPA, Police, and Narcotics Agency Issue Joint Enforcement Directive

CompanyDrug

FDA Grants Priority Review to Merck, Astellas, and Pfizer’s sBLA for Padcev-Pembrolizumab Combo in Perioperative Muscle-Invasive Bladder Cancer